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Germany studied by Poetsch et al (2000), compared with 61% (49
of 80 chromosomes) and 5% (four of 80 chromosomes) in the
Australian samples in our study. The similarity in polymorphism
frequencies indicates that there is no signi®cant difference in
genetic background between the two populations that may account
for the major difference in reported mutation frequency. It is not
known whether differences in environment could account for the
discrepancy; however, it is dif®cult to envisage how the major
environmental risk factor for melanoma development (exposure to
ultraviolet radiation; Whiteman and Green, 1999) could contribute
to the difference. Unless one invokes an environmental carcinogen
other than ultraviolet radiation, it seems more likely that there
would be less somatic mutations detected in north-eastern
Germany than in Australia.
Overall, in stark contrast to the study of Poetsch et al (2000),
our results do not indicate a signi®cant role for TTC4
mutations in melanoma development. Although TTC4 initially
appeared a good candidate, the search for tumor suppressor
genes on 1p continues.
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Expression of the 90K Tumor-Associated Protein in Benign
and Malignant Melanocytic Lesions
To the Editor:
Histopathologic differentiation of melanoma from benign melano-
cytic lesions can be extremely dif®cult (Barnhill et al, 1999; Reed,
1999), as a subset of melanomas mimic conventional (Suster et al,
1987; Wong et al, 1995) or Spitz's nevi (Muhlbauer et al, 1983;
Smith et al, 1989; Wong et al, 1995), but behave aggressively (Reed
et al, 1975; Reed, 1978; Muhlbauer et al, 1983; Phillips et al, 1986).
Therefore, the identi®cation of molecular markers that allow an
accurate diagnosis of melanoma is of utmost importance. Studying
such markers could also improve the understanding of the biologic
events involved in the melanocyte transformation to a highly
invasive and metastatic tumor. 90K is a large oligomeric protein
composed of a » 90 kDa subunit, originally identi®ed as a tumor-
secreted antigen in the culture medium of human breast cancer cells
(Iacobelli et al, 1986). After cDNA cloning (Ullrich et al, 1994), the
sequence of 90K showed that it contained a cystein-rich domain,
which is homologous to that found in the SRCR group A family of
proteins and is strictly related to the immunoglobulin superfamily
(Resnick et al, 1994). 90K was identi®ed independently as a ligand
of the lactose-speci®c S-type lectin, galectin-3 (formerly known as
Mac-2), and also named Mac-2 binding protein (Koths et al, 1993).
90K is observed in many tissues and in biologic ¯uids (Koths et al,
1993; D'Ostilio et al, 1996) and is overexpressed by the majority of
human tumors (Iacobelli et al, 1986), with serum levels frequently
elevated, as in patients with melanoma (Natoli et al, 1994). In A375
Table I. 90K staining in benign and malignant melanocytic
lesions
Cases
Total cases
(no.)
Positive
cases (no.)
Distribution
pattern Score
Lentigo simplex 5 0
Junctional nevus 5 2 Diffuse +/±
Intradermal nevus 5 1 Focal +/±
Compound nevus 10 5 Focal (2)
Patchy (3)
+/±
Spitz's nevus 10 10 Diffuse +/++
Metastasizing
Spitz's nevus
2 2 Focal (1)
Diffuse (1)
+/++
Melanoma in nevusa 9 9 Diffuse ++/+++
In situ melanoma 6 6 Diffuse +++
Melanoma < 0.76 mm 16 16 Diffuse (12)
Patchy (4)
++/+++
Melanoma > 0.76 to
< 3.00 mm
Melanoma > 3.00 mm
14
8
14
8
Diffuse (10)
Patchy (4)
Diffuse (4)
Patchy (4)
++/+++
++/+++
Cutaneous metastasis 6 6 Diffuse +/++
Nodal metastasis 3 3 Diffuse +/++
Bone metastasis 1 1 Focal ++
aResidual nevi were negative.
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human melanoma cells, 90K was found to promote homotypic
cell±cell adhesion by cross-linking of surface-bound galectin-3
residues (Inohara et al, 1996). Results from binding studies in vitro
demonstrated b1 integrin-mediated cell adhesion for 90K, as well as
interactions with some collagens and ®bronectin (Sasaki et al, 1998).
This suggests that 90K may play a part in embolization of
disseminating tumor cells in circulation and favors the progression
and metastatization. In this study, we veri®ed whether 90K could
be a reliable immunohistochemical marker of melanoma. We also
evaluated the ability of melanoma cells to adhere to 90K and other
extracellular matrix proteins.
Pathologic specimens, achieved from the section of Pathologic
Anatomy, comprehended the series of benign and malignant
melanocytic lesions listed in Table I. An immunohistochemical
reaction was performed using the anti-90K monoclonal antibody
1A4.22 (Tinari et al, 1997), and results were evaluated as positive or
negative cytoplasmic staining, scored in three grades (+, ++, +++)
and in three patterns of distribution (diffuse, focal, patchy); weak
staining was recorded as +/±. Cell adhesion assay was performed on
cells of the human melanoma cell line MEL-8863, from metastatic
human melanoma (Mecchia et al, 2000), using recombinant 90K
protein (Ullrich et al, 1994), laminin, and ®bronectin (Calbiochem,
San Diego, CA). The immunohistochemical results (see Table I
and Fig 1) demonstrated that all 65 malignant lesions, including
metastasizing Spitz's nevi and metastases, were positively stained
(++/+++); however, only 18 of 44 benign lesions (also including
the nine residual nevi in melanomas) gave a positive reaction,
which was weak (+/±) in eight cases, and mild or moderate (+/++)
in the remaining 10, represented by Spitz's nevi. Altogether these
results demonstrated that the speci®city and sensitivity of 90K in
differentiating melanocytic lesions is 59.09% and 100%, respectively
(Table II). Cell adhesion experiments showed adhesion of MEL-
8863 to 90K, laminin and ®bronectin higher than adhesion to the
negative control bovine serum albumin (p < 0.0001) (Fig 2A),
®bronectin being the best substrate. Competition experiments were
also performed and the results are shown in Fig 2(B).
Studies on markers of malignancy in melanoma have focused
mainly on oncogene alterations (Newton Bishop, 1997), but little is
known about other molecules, such as glycoconjugate ligands, that
interact with extracellular matrix and may be related to malignant
transformation and tumor progression. In this study, 90K appeared
to represent a potential marker of melanocytic cell transformation
and a factor possibly involved in tumor invasion and metastasis.
Although the expression of 90K is not absolute in distinguishing
between benign and malignant lesions, this marker was consistently
expressed in all types of melanoma, but not in normal melanocytes
at the dermoepidermal junction nor in conventional nevi. Only a
minority of these nevi showed a weak and usually focal staining.
Figure 1. Immunohistochemical staining pro-
®le for 90K. Sections from paraformaldehyde-
®xed and paraf®n-embedded tissues were immersed
in ethylenediamine tetraacetic acid buffer at pH 6.5
and pretreated in a microwave oven at 360 W
for 30 min; endogenous peroxidase activity was
quenched with 3% hydrogen peroxide for 10 min
at room temperature; sections were incubated with
anti-90K monoclonal antibody 1A4.22 (Tinari et al,
1997) for 30 min at room temperature, then were
treated with the LSAB Plus System (streptavidin±
biotin, LabVision, Fremont, CA); diamino-
benzidine was used as chromogene; sections were
counterstained with hematoxylin for 2 min. A
positive control (breast carcinoma) and a negative
control for each case studied were included.
Negative normal melanocytes at the dermo-
epidermal junction (A) and negative cells in
compound nevus (B); positive melanoma cells
compared with negative nevus cell in a case of
melanoma arisen in nevus (C); strong positivity in
``in situ'' melanoma (D) and in invasive melanoma
(E); the same invasive melanoma as negative
control after incubation without the primary
antibody (F); moderate positivity in Spitz's nevus
(G) and in metastasizing Spitz's nevus (H); positive
cutaneous (I) and lymph node (L) metastases. Scale
bar: 100 mm.
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Also, in melanomas arising in nevus, the benign part of the lesion
was negative, whereas the melanoma cells were strongly positive.
Metastases were immunohistochemically positive for 90K (con-
®rmed by immunoblotting, not shown), thus providing evidence
that 90K is expressed also by secondary lesions. On the other hand,
90K does not appear to be of value in differentiating Spitz's nevus
from melanoma. Indeed, Spitz's nevi showed a diffuse, although
less intense, positivity when compared with melanoma, and a
similar positivity was observed in the two cases of metastasizing
Spitz's nevus. Intriguingly, these data also suggest a role for 90K as
an early marker of neoplastic transformation of melanocytic lesions,
as well as raise some questions about the real nature of Spitz's nevus.
This is further substantiated by the ®nding that 90K expression was
stronger and more diffuse in ``in situ'' melanoma than in in®ltrating
lesions and metastases.
Our ®ndings show that the expression of 90K can help to
distinguish between benign and malignant melanocytic lesions,
with the exception of Spitz's nevus, which presents roughly the
same degree of expression of malignant melanoma. There was no
difference in the expression between melanomas of different
thickness, with the exception of the stronger positivity characteriz-
ing the ``in situ'' lesions. Therefore, 90K does not seem to represent
a prognostic factor that may predict the clinical outcome for
patients.
Our in vitro experiments show that this protein, absorbed on a
plastic substrate, causes the adhesion of melanoma cells through a
b1-integrin-mediated process. It has recently been documented
that 90K is a cell-adhesive, secreted glycoprotein that accumulates
in the extracellular matrix (Sasaki et al, 1998). As b1-integrins are
important components of the adhesion receptor repertoire on
melanoma cells (Schadendorf et al, 1993; Hieken et al, 1995), the
interaction between 90K present in the extracellular matrix and b1-
integrins on the cell surface may play a part in the interaction
between tumor cells and surrounding microenvironment; however,
our immunohistochemical data do not determine whether this
favors a more invasive behavior.
In conclusion, this study demonstrated that 90K is highly
expressed in melanoma as compared with normal melanocytes and
benign nevi. Our data suggest that the immunohistochemical
evaluation of 90K could potentially provide useful diagnostic
information in selected patients with melanoma.
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Dendritic Epidermal T Cells (DETC) are Diminished in
Integrin aE(CD103)-De®cient Mice
To the Editor:
A unique cell population of Thy-1+ dendritic epidermal cells
resides within murine epidermis (Bergstresser et al, 1983;
Tschachler et al, 1983). When it was recognized that this
population belongs to the lineage of gdTCR+ T lymphocytes,
they were named dendritic epidermal T cells (DETC) (Koning et
al, 1987; Kuziel et al, 1987; Stingl et al, 1987a; 1987b). DETC
exhibit a very limited diversity of TCR g and d gene usage with
very little junctional diversity, and most, if not all, bear the TCR
Vg3-Jg1-Cg1/Vd1-Dd2-Jd2-Cd (Asarnow et al, 1988, 1989;
Havran and Allison, 1988; Havran et al, 1989). Thymic origin of
DETC was strongly suggested by the observation that TCR-Vg3+
thymocytes [nomenclature according to Garman et al equivalent to
the Vg5 designation by Tonegawa and Heilig (Hayday and Pao,
1998)] appear at days 14±15 of gestational life, and disappear from
the thymus before their ®rst appearance within the epidermis at
days 17±19 of gestation (Havran and Allison, 1988). In addition,
implantation of day-14 thymic lobes from normal mice into
athymic nude mice (which lack Vg3+ DETC) resulted in the
appearance of an epidermal CD3+/Vg3+ population of DETC
(Havran and Allison, 1990). Whereas some experimental evidence
suggested that DETC participate in tolerance induction, elicitation
of contact hypersensitivity, tumor rejection, and other immuno-
logic functions (Tigelaar and Lewis, 1995; Girardi et al, 2001),
many aspects of their biologic role remain unknown. More
recently, it was found that integrin aE(CD103)b7 is expressed
around day 16 of gestation by TCR-Vg3+ thymocytes, and it was
hypothesized that this adhesion receptor is involved in epidermal
localization of DETC (Lefrancois et al, 1994). This suggestion was
consistent with the known functions of aE(CD103)b7 on intestinal
intraepithelial T lymphocytes, where it mediates adhesion to the
epithelial cell surface molecule E-cadherin (Cepek et al, 1994;
Karecla et al, 1995), a counter-receptor that is also constitutively
expressed by epidermal keratinocytes (Takeichi, 1990). Recently,
we demonstrated that aE(CD103)b7 mediates, at least in part,
epidermal localization of some CD8+ T lymphocytes in human
in¯ammatory skin disorders. This was based primarily upon
antibody-mediated blocking of adhesive functions of cultured T
lymphocytes expressing aE(CD103)b7 (Pauls et al, 2001). There is
no experimental evidence thus far, however, supporting the
hypothesis that integrin aE(CD103)b7 is involved in epidermal
localization of murine DETC.
In order to directly investigate the effect of integrin aE(CD103)
on DETC in vivo, we have analyzed wildtype mice and mice
lacking expression of the aE(CD103) integrin subunit, whose
generation and characterization was described recently (SchoÈn et al,
1999, 2000). Given that considerable strain-dependent differences
in the numbers of DETC have been reported, and as BALB/c mice
(the strain in which the aE-de®cient mice were ®rst generated)
have signi®cantly fewer DETC than other inbred strains
(Bergstresser et al, 1983), the aE(CD103)-de®cient animals were
backcrossed for ®ve to seven generations into the C57BL/6 strain
and then analyzed for DETC number.
In our initial experiments, the presence of DETC within the
epidermis was assessed by immunohistochemical analysis (ABC
immunoperoxidase method according to the manufacturer's
instructions; Vector, Burlingame, CA) using monoclonal antibodies
speci®c for CD3e (clone 500A), integrin aE(CD103) (clone 2E7),
TCR Vg3 (clone 536), and an isotype-matched control mono-
clonal antibody (clone Ha4/8, hamster IgGk monoclonal anti-
bodies purchased from PharMingen, San Diego, CA). As expected,
aE(CD103) was not expressed in the skin of aE(CD103)-de®cient
mice, whereas it was readily detected on numerous cells of
dendritic morphology within the epidermis of wildtype (aE+/+)
mice (Fig 1). Interestingly, when CD3+/Vg3+ DETC were
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